e-learning
resources
Milan 2017
Monday, 11.09.2017
Functional genomics knowledge in parenchymal and bronchial diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Association between AGTTGFB1ESR1, and VDR gene variants with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis (PS) clinical features
A. Ulitina (St Petersburg, Russian Federation)
Source:
International Congress 2017 – Functional genomics knowledge in parenchymal and bronchial diseases
Session:
Functional genomics knowledge in parenchymal and bronchial diseases
Session type:
Oral Presentation
Number:
2906
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Ulitina (St Petersburg, Russian Federation). Association between AGTTGFB1ESR1, and VDR gene variants with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis (PS) clinical features. 2906
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Pulmonary sarcoidosis
Definition and history of sarcoidosis
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017
Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Genetic predictors of idiopathic pulmonary fibrosis (IPF) prognosis
Source: Eur Respir J 2006; 28: Suppl. 50, 830s
Year: 2006
Morphological and immunohistochemical characteristics of pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2002; 20: Suppl. 38, 586s
Year: 2002
The circulating metabolome in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019
Polymorphism of the genes of xenobiothics detoxification in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2004; 24: Suppl. 48, 536s
Year: 2004
Prognostic evaluation in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2015 – IPF pathogenesis
Year: 2015
The similarity and difference of pathology of pulmonary arterioles in COPD and idiopathic lung fibrosis (IPF)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR)
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020
Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD)
Source: Eur Respir J 2004; 24: Suppl. 48, 533s
Year: 2004
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Analysis of pulmonary function in patients with idiopathic pulmonary fibrosis (IPF): how stable is stable IPF?
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009
Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2006 - Clinical physiology
Year: 2006
Treatment of idiopathic pulmonary fibrosis (IPF) with pentoxifylline (POF)
Source: Eur Respir J 2007; 30: Suppl. 51, 121s
Year: 2007
Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 354s
Year: 2006
Cykine/receptor inflammatory profile in different types of idiopathic intestitial pneumonias (IIPs). Key role of Fas Ligand recruvation in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept